# An inherited EGFR variant marks lung cancer risk > A Science study of more than 3.3 million people links germline EGFR T790M to substantial lung cancer risk, especially in never-smokers, but it does not establish population-wide testing or CT screening rules. _Source: Peer-reviewed Science study, verified through PubMed, Europe PMC, Crossref, an independent prospective familial cohort, NCI guidance and current USPSTF screening guidance · 2026-10-03 · 7 min read · Verified against primary sources_ Canonical: https://iyu.app/e/germline-egfr-t790m-lung-cancer-risk ## The 60-second version A Science analysis of more than 3.3 million people links inherited EGFR T790M to substantial lung cancer risk, especially in never-smokers. **Key points** - Germline T790M is inherited and differs from a T790M change acquired inside a lung tumor during treatment. - The study found no increased risk across 17 other cancers and no interaction with its polygenic risk score. - A Southern Appalachian founder event about 200 to 225 years ago helps explain higher US prevalence in some descendant populations. - Independent family cohorts support real predisposition but are too selected to provide a universal lifetime-risk number. - Current US low-dose CT guidance remains based mainly on age and smoking history, so carrier surveillance requires specialist judgment and more evidence. **Verdict.** The paper makes germline T790M a clearer high-risk signal for selected families, not a case for mass consumer testing or unsupervised CT screening. ## Full explainer A peer-reviewed [Science study](https://doi.org/10.1126/science.aec0473) of more than **3.3 million people** found that the rare germline **EGFR T790M** variant was strongly associated with lung cancer, including among never-smokers. It strengthens the evidence for an inherited lung-cancer syndrome, but does not create a population-wide testing or CT-screening rule. > **⚑ Caveat:** The public abstract reports relative associations, not one absolute lifetime-risk figure for every carrier. It is also not a screening trial. Do not use the result to order consumer testing or repeated CT scans without clinical genetics and lung-specialist advice. ### Definition — Germline and tumor T790M are different findings A **germline** variant is inherited through an egg or sperm and can be present throughout the body. A **somatic** variant arises in particular cells. In lung cancer, T790M is widely known as a tumor resistance change that can appear after EGFR-targeted treatment; this study examined the inherited form. - **Germline T790M:** Inherited predisposition; confirmation uses an appropriate non-tumor sample and has implications for relatives. - **Tumor T790M:** A change detected in cancer cells; it may be acquired during tumor evolution and can affect treatment decisions. - **Tumor result suggesting germline:** A reason to consider genetics referral and confirmatory testing, not proof that the variant was inherited. ### Study — What the large analysis found - **>3.3m** — people included in the analysis - **17** — other cancers without increased risk - **200-225 years** — estimated age of the founder event - **1 variant** — rare EGFR T790M germline signal The variant was significantly associated with lung cancer, and the association was several-fold stronger in never-smokers. The authors report that its modeled risk exceeded smoking-associated risk in their analyses. That comparison describes a rare carrier subgroup; it does **not** overturn smoking as the leading preventable cause of lung cancer across the population. The team found no increased risk for 17 other cancers and no interaction with a polygenic risk score. The latter means the measured T790M association did not clearly vary with the separate score built from many common variants; it does not make the rest of a person's genetic or environmental background irrelevant. ### Population history — A founder event explains a US cluster Geographic and ancestry analyses found higher T790M prevalence in the United States than in British- and Irish-descendant comparison populations. The pattern points to a Southern Appalachian founder event about 200 to 225 years ago and descendants of British, Irish and African ancestry. > A founder effect explains how a rare variant spread through descendants; it does not turn a region or ancestry label into a genetic diagnosis. ### Independent evidence — Family cohorts support risk but not a universal probability An independent [prospective familial study](https://pmc.ncbi.nlm.nih.gov/articles/PMC12153668/) previously reported lung cancer in 50 of 91 confirmed or obligate germline EGFR pathogenic-variant carriers across 39 kindreds. It also found variable penetrance and frequent additional EGFR driver changes in tumors. Because families entered through suspicious clinical findings, those proportions should not be treated as the lifetime risk for an unselected carrier. ### Clinical meaning — Who may need genetics review The result is most actionable when T790M appears unexpectedly before treatment, when lung cancer occurs unusually young, or when multiple relatives have lung cancer, especially EGFR-mutant disease. A genetics professional can review the pedigree, choose confirmatory testing and explain implications for relatives. The [National Cancer Institute](https://www.cancer.gov/about-cancer/causes-prevention/genetics) distinguishes tumor biomarker testing from inherited-risk testing and advises that not everyone needs germline testing. A direct-to-consumer result is not a substitute for clinical confirmation and counseling. ### Screening — Evidence has moved faster than guidelines Current [USPSTF guidance](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening) recommends annual low-dose CT mainly by age and smoking history: ages 50 to 80, at least 20 pack-years, and current smoking or quitting within 15 years. It does not provide a separate pathway for never-smokers with germline T790M. - **What is established:** Germline T790M is a rare inherited lung-cancer predisposition variant supported by a very large association study and familial cohorts. - **What remains uncertain:** The best age, interval and eligibility rules for CT surveillance in carriers, and the balance of benefit against false positives and radiation. - **What to do now:** Use clinical genetics and specialist review for selected families; continue smoking prevention and established screening criteria for the wider population. ### Takeaway — The finding narrows a blind spot in lung cancer risk Smoking remains the dominant preventable risk, yet it is not the whole story. This study identifies a rare group whose inherited risk can be substantial even without smoking. The next step is prospective work that turns genetic identification into evidence-based surveillance, rather than assuming that more testing and scanning must automatically help. ## Primary sources - [Science study: Germline EGFR T790M mutation and lung cancer risk](https://doi.org/10.1126/science.aec0473) - [PubMed record 42752144](https://pubmed.ncbi.nlm.nih.gov/42752144/) - [Europe PMC bibliographic record](https://europepmc.org/article/MED/42752144) - [Science perspective: In search of past genetics](https://pubmed.ncbi.nlm.nih.gov/42752154/) - [Prospective familial EGFR cohort in Journal of Clinical Oncology](https://pmc.ncbi.nlm.nih.gov/articles/PMC12153668/) - [NCI: The Genetics of Cancer](https://www.cancer.gov/about-cancer/causes-prevention/genetics) - [USPSTF lung cancer screening recommendation](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening) - [Telegram post 1527 (CNSmydream)](https://t.me/CNSmydream/1527) --- _Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._